People could also gain weight again without healthy habits
The category of medication matters less than your actual food intake and rate of loss, which is what you and your clinician should be watching
19 The dual GIP/GLP-1 RA tirzepatide has demonstrated a similar but sometimes more pronounced GI profile compared with semaglutide in clinical-development programs
2p, 3l and 5af
The GLP-1s that were originally marketed as a diabetes treatment include semaglutide, brand name Ozempic, liraglutide, brand name Victoza, dulaglutide, brand name Trulicity, and the latest GLP-1 to the market, tirzepitide, brand name Mounjaro, which is a combination GIP/GLP-1
Avoidance also may derive from the number of people with obesity being so largefar larger than the number with diabetesand therefore more costly to treat, the authors note